Literature DB >> 19995394

Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study.

Therese M-L Andersson1, Paul C Lambert, Asa Rangert Derolf, Sigurdur Yngvi Kristinsson, Sandra Eloranta, Ola Landgren, Magnus Björkholm, Paul W Dickman.   

Abstract

Large age-dependent differences in temporal trends in 1- and 5-year relative survival have been observed in patients with acute myeloid leukaemia (AML) in Sweden. This investigation used an alternative approach to studying patient survival that simultaneously estimated the proportion of patients cured from their cancer and the survival of the 'uncured'. We conducted a population-based study including 6439 AML patients aged 19-80 years in Sweden between 1973 and 2001. Mixture cure models were estimated, with age at diagnosis categorised (19-40, 41-60, 61-70 and 71-80) and year of diagnosis modelled using splines. In 1975 the cure proportion was < or =6% in all age groups and the median survival time for 'uncured' patients was <0.5 years. In 2000 the cure proportion was 68% (95% confidence interval 56-77%) in the youngest group, and 32% (25-39%), 8% (3-21%), and 4% (2-8%) in the other groups, respectively. The median survival times for 'uncured' were 0.74 (0.43-1.26), 0.71 (0.53-0.97), 0.69 (0.51-0.95) and 0.37 (0.31-0.44) years, respectively. A dramatic improvement in the cure proportion was seen in younger patients, whereas improvement in older ages was mainly within the survival of the 'uncured'. This novel approach of analysing survival data could be a valuable tool for physicians, patients, health care planners and health economists.

Entities:  

Mesh:

Year:  2009        PMID: 19995394     DOI: 10.1111/j.1365-2141.2009.08026.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types.

Authors:  L Dal Maso; S Guzzinati; C Buzzoni; R Capocaccia; D Serraino; A Caldarella; A P Dei Tos; F Falcini; M Autelitano; G Masanotti; S Ferretti; F Tisano; U Tirelli; E Crocetti; R De Angelis; S Virdone; A Zucchetto; A Gigli; S Francisci; P Baili; G Gatta; M Castaing; R Zanetti; P Contiero; E Bidoli; M Vercelli; M Michiara; M Federico; G Senatore; F Pannozzo; M Vicentini; A Bulatko; D R Pirino; M Gentilini; M Fusco; A Giacomin; A C Fanetti; R Cusimano
Journal:  Ann Oncol       Date:  2014-08-22       Impact factor: 32.976

2.  Prognosis and cure of long-term cancer survivors: A population-based estimation.

Authors:  Luigino Dal Maso; Chiara Panato; Stefano Guzzinati; Diego Serraino; Silvia Francisci; Laura Botta; Riccardo Capocaccia; Andrea Tavilla; Anna Gigli; Emanuele Crocetti; Massimo Rugge; Giovanna Tagliabue; Rosa Angela Filiberti; Giuliano Carrozzi; Maria Michiara; Stefano Ferretti; Rosaria Cesaraccio; Rosario Tumino; Fabio Falcini; Fabrizio Stracci; Antonietta Torrisi; Guido Mazzoleni; Mario Fusco; Stefano Rosso; Francesco Tisano; Anna Clara Fanetti; Giovanna Maria Sini; Carlotta Buzzoni; Roberta De Angelis
Journal:  Cancer Med       Date:  2019-06-17       Impact factor: 4.452

Review 3.  Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.

Authors:  Masayuki Yamashita; Paul V Dellorusso; Oakley C Olson; Emmanuelle Passegué
Journal:  Nat Rev Cancer       Date:  2020-05-15       Impact factor: 60.716

4.  Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life.

Authors:  H Bower; T M-L Andersson; M Björkholm; P W Dickman; P C Lambert; Å R Derolf
Journal:  Blood Cancer J       Date:  2016-02-05       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.